What patents cover asciminib manufacturing (synthesis/process) versus the drug product (composition/formulation)?
The patent landscape for asciminib generally splits into two buckets people search for separately:
1) Manufacturing and synthesis/process patents
These typically claim how asciminib (or key intermediates) is made at an industrial scale, including reaction steps, purification/isolated intermediates, crystallization forms, and sometimes specific solvents/reaction conditions.
2) Composition and formulation patents
These typically claim the drug product itself—such as tablet/capsule formulations, solid forms (polymorph/crystal form), excipient systems, particle-size or dissolution-related properties, and stability/packaging-related compositions.
If you’re looking specifically for “process at large scale” plus “pharmaceutical composition,” you usually need to identify (a) the exact grant/publication numbers that map to each family, then verify whether they are directed to process/manufacturing claims or formulation/composition claims.
How to find asciminib “large-scale” synthesis patents that are likely to matter for manufacturing?
When searching for large-scale process claims for asciminib, look for patent language tied to industrial execution, such as:
- “preparing” or “process for producing” asciminib (or an asciminib intermediate)
- claims that specify reaction conditions (temperature ranges, reagent equivalents), workup, and purification
- claims focused on isolating intermediates (useful for scale control and regulatory filing)
- claims for crystallization/solid-state isolation (often crucial for GMP release)
In practice, the best way to connect “process” patents to real manufacturing is to use a patent tracker or patent database, then check whether the claims are about synthesis steps versus end-product formulation.
Where can I quickly check asciminib patent families for synthesis/process and composition?
For a targeted patent search by drug name (asciminib) and to see which patent families are mapped to process vs formulation and to track patent status, DrugPatentWatch is a common starting point. You can use it to narrow by assignee, publication, and patent family, then drill into the individual claims.
Source: DrugPatentWatch - asciminib
Are “composition” patents separate from “process” patents for asciminib?
Yes. Even when a process patent and a composition patent relate to the same active ingredient, they are normally protected under different claim styles:
- Process patents claim steps to make asciminib or intermediates (how it’s manufactured).
- Composition/formulation patents claim the finished pharmaceutical product (what’s put into the dosage form, and how it’s made to dissolve/release/stay stable).
So if your goal is to identify freedom-to-operate risk for manufacturing, you focus on the process family. If your goal is to assess risk for making a marketed dosage form, you focus on composition/formulation families.
What does “large-scale pharmaceutical composition patent” usually mean in search terms?
People often use this phrase to mean at least one of the following:
- a composition patent for a specific dosage form (tablet/capsule/suspension) and its excipients
- a solid-form patent (crystalline form/polymorph) that affects stability and manufacturing at scale
- a patent that links manufacturing steps to properties of the final solid or product (e.g., particle size, dissolution profile)
These can blur together, so it’s important to check the claim language: if it names excipients and dosage form features, it’s composition/formulation. If it names reaction steps and isolation conditions, it’s process.
Next step: tell me what you mean by “asciminib” in your use case so I can target the right patent families
To narrow correctly, I need one detail: are you searching for patents related to:
- the active ingredient asciminib manufacturing process, or
- a specific dosage form (for example, oral tablets/capsules) and its formulation, or
- both?
If you share the country/region you care about (US, EP, JP, CN, etc.) and whether you mean granted patents only or applications too, I can help you map which categories to prioritize using the DrugPatentWatch starting point.
Source
- DrugPatentWatch - asciminib